

Supporting Information

Photochemistry of *N*-(selenoalkyl)-Phthalimides. Formation of *N*, Se-heterocyclic systems

Gabriela Oksdath-Mansilla, Adrián A. Heredia, Juan E. Argiello* and Alicia B. Peñéñory*

Table of Contents

Figure S1: UV-visible absorption spectra of compounds 1a-e in acetonitrile	2
Figure S2: Florescence spectra of compounds 1a-e and <i>N</i> -methylphthalimide in acetonitrile	2
Figure S3: Cyclic voltammogram of 1b in acetonitrile.....	3
Figure S4: Cyclic voltammogram of <i>N</i> -methylphthalimide in acetonitrile	3
General Methods:	4
General procedure for the synthesis of selenoalkyl phthalimide derivates.....	4
General procedure for the photocyclization of selenoalkyl phthalimides derivates	4
<i>N</i> -(2-selenomehtyl)ethyl)phthalimide (1a)	8
<i>N</i> -(3-selenomethyl)propyl)phthalimide (1b)	10
<i>N</i> -(3-selenobenzyl)propyl)phthalimide (1c)	12
<i>N</i> -(4-selenomethyl)butyl)phthalimide (1d)	14
<i>N</i> -(5-selenomethyl)pentyl)phthalimide (1e)	16
10b-hydroxy-1,3,4,10b-tetrahydro-6H-[1,4]selenazino[3,4-a]isoindol-6-one (2a)	18
11b-hydroxy-1,4,5,11b-tetrahydro-3H,7H-[1,4]selenazepino[3,4-a]isoindol-7-one (2b)	20
9b-hydroxy-1-(selenomethyl)-1,2,3,9b-tetrahydro-5H-pyrrolo[2,1-a]isoindol-5-one (3b)	22
9b-hydroxy-1,2,3,9b-tetrahydro-5H-pyrrolo[2,1-a]isoindol-5-one (4b).....	30
5H-pyrrolo[2,1-a]isoindol-5-one (5b).....	31
10b-hydroxy-1-(selenomethyl)-1,3,4,10b-tetrahydropyrido[2,1-a]isoindol-6(2H)-one (3d)	32
13b-hydroxy-1,4,5,6,7,13b-hexahydro-3H,9H-[1,4]selenazonino[3,4-a]isoindol-9-one (2e)	42
References	43




Figure S1: UV-visible absorption spectra of compounds **1a**, **b**, **d** and *N*-methyl-phthalimide (0.6 mM) in acetonitrile




Figure S2: Florescence spectra of compounds **1a**, **b**, **d** and *N*-methyl-phthalimide in acetonitrile, absorption matched to 0.1 at 290 nm.




Figure S3: Cyclic voltammogram of **1b** (1.6mM) in acetonitrile with 0.1M TBABF₄ vs SCE at a glassy carbon electrode at room temperature, sweep rate = 0.1 V s⁻¹




Figure S4: Cyclic voltammogram of *N*-methylphthalimide (1.3mM) in acetonitrile with 0.1M TBABF₄ vs SCE at a glassy carbon electrode at room temperature, sweep rate = 0.1 V s⁻¹

General Methods: Phthalimide, *N*-(2-chloroethyl)-phthalimide, 1,3-dibromopropane, 1,5-dibromopentane, dimethyldiselenide, diphenyldiselenide, KOH, Na°, benzophenone, 4,4-dimethoxy-benzophenone, xanthone and thioxantone were purchased from Sigma-Aldrich Chemicals Co. Acetonitrile, acetone, dimethylformamide (Merck HPLC grade) were used as purchased without any further purification and stored over molecular sieves (4A°). Toluene was distilled with Na/benzophenone and stored over nitrogen atmosphere. Water was filtered Milli-Q purity.

The *N*-(haloalkyl)-phthalimides were synthesized and purified according to the previously reported.

General procedure for the synthesis of selenoalkyl phthalimide derivates: Into a three-necked, 250-mL, round-bottomed flask equipped with a coldfinger condenser charged with dry ice-ethanol, a nitrogen inlet, and a magnetic stirrer was condensed 150 mL of ammonia previously dried with Na metal under nitrogen. The dialkyl diselenide (1.1 mmol) was added and then 2 equiv of Na metal in small pieces, waiting for bleaching between each addition. After of the last addition the ammonia was allowed to evaporate and DMF was introduced together with *N*-(haloalkyl)-phthalimide (1 mmol). The crude reaction was dissolved in water and next extracted with diethyl ether. The product was further purified by column chromatography using a mixture of petroleum ether and ethylic ether as the eluent.

General procedure for the photocyclization of selenoalkyl phthalimides derivates: A solution of **1** (0.2 mmol) in acetone (2-5 mM) was irradiated at 300 nm (lamps: 16 x 3000 Å, 300 ± 10 nm) in a Pyrex tube for 24 h while being purged with a stream of nitrogen and cooled to nr. 10 °C. After removal of the solvent under reduced pressure the residue was purified by column chromatography.

***N*-(2-selenomehtyl)ethylphthalimide (**1a**): (yield 65%):** **¹H NMR (400 MHz, CDCl₃):** δ = 2.07 (s, 3H), 2.83 (t, *J* = 7.2 Hz, 2H), 3.95 (t, *J* = 7.2 Hz, 2H), 7.73 (dd, *J* = 5.6, 3.2 Hz, 2H), 7.85 (dd, *J* = 5.6, 3.2 Hz, 2H); **¹³C NMR (100 MHz, CDCl₃):** δ = 4.2, 22.7, 37.4, 123.3, 132.0, 134.0, 168.1; **⁷⁷Se NMR (76 MHz, CDCl₃):** δ = 61.5. **GC-MS (EI) *m/z* 269**

(M⁺, 39), 174 (86), 160 (82), 130 (36), 122 (100), 76 (47). **HRMS (ESI-TOF)** *m/z* calcd for C₁₁H₁₂NO₂Se: 270.0028 [M+H]⁺, found: 270.0030.

N-(3-selenomethyl)propylphthalimide (1b): (yield 76%): **¹H NMR (400 MHz, CDCl₃):** δ = 2.00 (s, 3H), 2.05 (q, *J* = 7.0 Hz, 2H), 2.56 (t, *J* = 7.0 Hz, 2H), 3.79 (t, *J* = 7.0 Hz, 2H), 7.72 (dd, *J* = 5.4, 3.1 Hz, 2H), 7.85 (dd, *J* = 5.4, 3.1 Hz, 2H); **¹³C NMR (100 MHz, CDCl₃):** δ = 4.0, 21.8, 28.9, 38.0, 123.2, 132.1, 133.9, 168.3; **⁷⁷Se NMR (76 MHz, CDCl₃):** δ = 80.2. **GC-MS (EI)** *m/z* 283 (M⁺, 12), 188 (100), 169 (15), 160 (85), 148 (8), 130 (33), 104 (18), 77 (24), 76 (24), 41 (35). **HRMS (ESI-TOF)** *m/z* calcd for C₁₂H₁₄NO₂Se: 284.0185 [M+H]⁺, found: 284.0195.

N-(3-selenobenzyl)propylphthalimide (1c): (yield 63%): **¹H NMR (400 MHz, CDCl₃):** δ = 1.98 (q, *J* = 7.2, 2H), 2.46 (t, *J* = 8.0 Hz, 2H), 3.73 (t, *J* = 7.2 Hz, 2H), 3.78 (s, 2H), 7.11-7.26 (m, 5H), 7.72 (dd, *J* = 5.6Hz, 3.2 Hz, 2H), 7.84 (dd, *J* = 5.6, 3.2 Hz, 2H); **¹³C NMR (100 MHz, CDCl₃):** δ = 20.3, 26.9, 29.1, 38.0, 123.2, 126.7, 128.5, 128.8, 132.1, 134.0, 139.0, 168.3; **⁷⁷Se NMR (76 MHz, CDCl₃):** δ = 255.3. **GC-MS (EI)** *m/z* 359 (M⁺, 4), 268 (5), 188 (22), 160 (13), 91 (100), 65 (15). **HRMS (ESI-TOF)** *m/z* calcd for C₁₈H₁₇NNaO₂Se: 382.0317 [M+Na]⁺, found: 382.0325.

N-(4-selenomethyl)butylphthalimide (1d): (yield 65%): **¹H NMR (400 MHz, CDCl₃):** δ = 1.67 - 1.76 (m, 2H) 1.77 – 1.82 (m, 2H), 1.98 (s, 3H), 2.58 (t, *J* = 7.2 Hz, 2H), 3.72 (t, *J* = 7.0 Hz, 2H), 7.72 (dd, *J* = 5.5, 3.0 Hz, 2H), 7.85 (dd, *J* = 5.5, 3.0 Hz, 2H); **¹³C NMR (100 MHz, CDCl₃):** δ = 4.1 24.6, 27.4, 28.7, 37.4, 123.2, 132.1, 133.9, 168.4; **⁷⁷Se NMR (76 MHz, CDCl₃):** δ = 77.5. **GC-MS (EI)** *m/z* 297 (M⁺, 7), 202 (32), 160 (100), 130 (12), 77 (10). **HRMS (ESI-TOF)** *m/z* calcd for C₁₃H₁₅NNaO₂Se: 320.0161 [M+Na]⁺, found: 320.0167.

N-(5-selenomethyl)pentylphthalimide (1e): (yield 57%): **¹H NMR (400 MHz, CDCl₃):** δ = 1.41-1.49 (m, 2H), 1.67-1.75 (m, 4H), 1.97 (s, 3H), 2.53 (t, *J* = 7.3 Hz, 2H), 3.69 (t, *J* = 7.3 Hz, 2H), 7.68 (dd, *J* = 5.4, 3.04 Hz, 2H), 7.81 (dd, *J* = 5.4, 3.04 Hz, 2H); **¹³C NMR (100 MHz, CDCl₃):** δ = 4 (CH₃Se), 25.1, 27.0, 28.1, 29.7, 37.8, 123.2, 132.1, 133.9, 168.4; **⁷⁷Se NMR (76 MHz, CDCl₃):** δ = 77.0. **GC-MS (EI)** *m/z* 311 (M⁺, 12), 216 (53),

160 (100), 148 (13), 130 (24), 104 (10), 77 (15). **HRMS (ESI-TOF)** m/z calcd for C₁₄H₁₈NO₂Se: 312.0498 [M+H]⁺, found: 312.0505.

10b-hydroxy-1,3,4,10b-tetrahydro-6H-[1,4]selenazino[3,4-a]isoindol-6-one (2a): ¹**H NMR (400 MHz, CDCl₃)**: δ = 2.57 (dt, J = 14.4, 2.4 Hz, 1H), 2.75 (td, J = 12.4, 3.2 Hz, 1H), 2.89 (d, J = 12.4 Hz, 1H), 3.15 (d, J = 12.4 Hz, 1H), 3.45 (ddd, J = 14.2, 12.4, 3.2 Hz, 1H), 4.37 (s, 1H), 4.68 (dt, J = 14.4, 2.8 Hz, 1H), 7.51-7.55 (m, 1H), 7.58-7.64 (m, 2H), 7.81-7.83 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 18.9, 30.5, 37.8, 82.9, 121.6, 123.9, 130.1, 131.2, 132.3, 145.7, 165.1; ⁷⁷Se NMR (76 MHz, CDCl₃): δ = 74.7. GC-MS (EI) m/z 253 (24), 251 ([M-H₂O]⁺, 100), 249 (11), 238 (23), 236 (93), 234 (54), 170 (47), 159 (10), 129 (41), 115 (61), 102 (41), 89 (29), 75 (49). **HRMS (ESI-TOF)** m/z calcd for C₁₁H₁₁NNaO₂Se: 291.9848 [M+Na]⁺, found: 291.9859.

11b-hydroxy-1,4,5,11b-tetrahydro-3H,7H-[1,4]selenazepino[3,4-a]isoindol-7-one (2b): ¹**H NMR (400 MHz, CDCl₃)**: δ = 2.09 (q, J = 14.4 Hz, 2H), 2.64-2.67 (m, 2H), 3.09 (m, 1H), 3.15 (d, J = 14 Hz, 1H), 3.40 (d, J = 14 Hz, 1H), 3.50 (d, J = 14.8 Hz, 1H), 4.33 (s, 1H), 7.42-7.46 (m, 1H), 7.51-7.54 (m, 1H), 7.57-7.60 (m, 2H); ¹³C NMR (100 MHz, CDCl₃): δ = 25.6, 28.4, 34.1, 38.6, 92.2, 121.7, 123.0, 129.7, 131.5, 132.6, 146.3, 168.2; ⁷⁷Se NMR (76 MHz, CDCl₃): δ = 156.9. GC-MS (EI) m/z 265 ([M-H₂O]⁺, 75), 263 (40), 236 (45), 184 (100), 129 (21), 115 (10), 102 (26). **HRMS (ESI-TOF)** m/z calcd for C₁₂H₁₄NO₂Se: 284.0185 [M+H]⁺, found: 284.0204.

9b-hydroxy-1-(selenomethyl)-1,2,3,9b-tetrahydro-5H-pyrrolo[2,1-a]isoindol-5-one (3b): ¹**H NMR (400 MHz, CDCl₃)**: δ = 2.03 (s, 3H), 2.74 (m, 2H), 2.83 (m, 1H), 3.34 (d, J = 1.4 Hz, 1H), 3.44 (ddd, J = 11.3, 5.7, 4.2 Hz, 1H), 3.66 (dt, J = 11.3, 8.5 Hz, 1H), 7.50 (td, J = 7.5, 1.2 Hz, 1H), 7.59 (td, J = 7.5, 1.2 Hz, 1H), 7.67 (dt, J = 7.5, 1.2 Hz, 1H), 7.81 (dt, J = 7.5, 1.2 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 4.7, 35.7, 41.1, 44.6, 95.5, 122.8, 123.8, 130.2, 131.7, 132.8, 145.9, 169.8; ⁷⁷Se NMR (76 MHz, CDCl₃): δ = 88.5. GC-MS (EI) m/z 265 ([M-H₂O]⁺, 100), 263 (61), 250 (98), 169 (85), 142 (23), 115 (79). **HRMS (ESI-TOF)** m/z calcd for C₁₂H₁₃NNaO₂Se: 306.0004 [M+Na]⁺, found: 306.0030.

9b-hydroxy-1,2,3,9b-tetrahydro-5H-pyrrolo[2,1-a]isoindol-5-one (4b): ¹
H NMR (400 MHz, CDCl₃): δ = 1.61 – 1.49 (m, 1H), 2.40 – 2.23 (m, 2H), 2.73 – 2.53 (m, 1H), 3.51 – 3.32 (m, 1H), 2.91 (s, 1H), 3.65 (dt, J = 11.4, 8.5 Hz, 1H), 7.51 – 7.43 (m, 1H), 7.57 (t, J =


6.0 Hz, 2H), 7.64 (d, J = 7.5 Hz, 1H); **^{13}C NMR (100 MHz, CDCl_3)**: δ = 27.7, 34.7, 41.5, 96.5, 122.6, 123.7, 129.8, 131.7, 132.8, 147.2, 170.1. **GC-MS (EI)** m/z 171 ([M-H₂O]⁺, 83), 170 (100), 143 (18), 142 (21), 115 (21). **HRMS (ESI-TOF)** m/z calcd for $\text{C}_{11}\text{H}_{12}\text{NO}_2$: 190.0863 [M+H]⁺, found: 190.0887.

5H-pyrrolo[2,1-a]isoindol-5-one (5b): **^2H NMR (400 MHz, CDCl_3)**: δ = 6.17 (t, J = 3.1 Hz, 1H), 6.21 (dd, J = 3.1, 0.6 Hz, 1H), 7.01 (dd, J = 3.2, 0.7 Hz, 1H), 7.18 (td, J = 7.5, 0.8 Hz, 1H), 7.28 (d, J = 7.5 Hz, 1H), 7.43 (td, J = 7.6, 1.1 Hz, 1H), 7.64 (d, J = 7.5 Hz, 1H); **^{13}C NMR (100 MHz, CDCl_3)**: δ = 107.4, 116.7, 117.2, 119.5, 125.8, 127.2, 132.0, 134.5, 135.6, 136.4, 163.1. **GC-MS (EI)** m/z 169 (M⁺, 100), 140 (25), 114 (31).


10b-hydroxy-1-(selenomethyl)-1,3,4,10b-tetrahydropyrido[2,1-a]isoindol-6(2H)-one (3d): **^1H NMR (400 MHz, CDCl_3)**: δ = 1.52 – 1.37 (m, 1H), 1.84 – 1.75 (m, 1H), 2.05 (s, 3H), 2.21 – 2.12 (m, 1H), 2.33 (qd, J = 13.0, 3.7 Hz, 1H), 2.49 (dd, J = 13.0, 4.0 Hz, 1H), 3.00 (td, J = 13.0, 3.4 Hz, 1H), 3.73 (d, J = 1.6 Hz, 1H), 4.04 (dd, J = 13.0, 4.9 Hz, 1H), 7.39 (td, J = 7.5, 0.9 Hz, 1H), 7.53 (m, 2H), 8.28 (d, J = 7.6 Hz, 1H). **^{13}C NMR (100 MHz, CDCl_3)**: δ = 4.3, 27.1, 29.6, 35.5, 46.2, 88.5, 123.1, 124.5, 129.6, 130.8, 131.6, 147.1, 164.9. **^{77}Se NMR (76 MHz, CDCl_3)**: δ = 159.3. **GC-MS (EI)** m/z 279 ([M-H₂O]⁺, 100), 264 (99), 234 (19), 184 (69), 182 (99), 172 (39), 154 (26), 130 (26), 129 (28), 128 (39), 127 (42), 102 (41). **HRMS (ESI-TOF)** m/z calcd for $\text{C}_{13}\text{H}_{16}\text{NNaO}_2\text{Se}$: 320.0161 [M+Na]⁺, found: 320.0174.

13b-hydroxy-1,4,5,6,7,13b-hexahydro-3H,9H-[1,4]selenazonino[3,4-a]isoindol-9-one (2e): **^1H NMR (400 MHz, CDCl_3)**: δ = 1.49 - 1.57 (m, 2H), 1.66 - 1.74 (m, 1H), 1.78 - 1.86 (m, 2H), 2.03 - 2.15 (m, 1H), 2.52 - 2.58 (m, 1H), 2.63 – 2.69 (m, 1H), 3.28 (d, J = 14.1 Hz, 1H), 3.41 (m, 2H), 3.58 – 3.64 (m, 1H), 3.53 (s, 1H), 7.41 – 7.44 (m, 2H), 7.54 – 7.58 (m, 1H), 7.60 – 7.62 (m, 1H); **^{13}C NMR (100 MHz, CDCl_3)**: δ = 22.1, 24.4, 24.8, 26.8, 29.4, 38.0, 91.0, 121.3, 123.1, 129.9, 131.5, 132.4, 146.5, 169.0; **^{77}Se NMR (76 MHz, CDCl_3)**: δ = 117.5. **GC-MS (EI)** m/z 293 ([M-H₂O]⁺, 17), 236 (12), 212 (14), 198 (16), 184 (88), 158 (100), 146 (33), 130 (20), 115 (13), 102 (29), 89 (21). **HRMS (ESI-TOF)** m/z calcd for $\text{C}_{14}\text{H}_{17}\text{NNaO}_2\text{Se}$: 334.0317 [M+Na]⁺, found: 334.0343.


¹H NMR. *N*-(2-selenomehtyl)ethyl)phthalimide (1a)




¹³C NMR. *N*-(2-selenomehtyl)ethyl)phthalimide (1a)




^{77}Se NMR. *N*-(2-selenomehtyl)ethyl)phthalimide (1a**)**




¹H NMR. *N*-(3-selenomethyl)propylphthalimide (1b)




¹³C NMR. *N*-(3-selenomethyl)propylphthalimide (1b)




^{77}Se NMR. *N*-(3-selenomethyl)propylphthalimide (1b**)**




¹H NMR. *N*-(3-selenobenzyl)propylphthalimide (1c)




¹³C NMR. *N*-(3-selenobenzyl)propylphthalimide (1c)




^{77}Se NMR. *N*-(3-selenobenzyl)propylphthalimide (1c)




¹H NMR. N-(4-selenomethyl)butylphthalimide (1d).




¹³C NMR. N-(4-selenomethyl)butylphthalimide (1d).




^{77}Se NMR. *N*-(4-selenomethyl)butylphthalimide (1d**)**




¹H NMR. *N*-(5-selenomethyl)pentylphthalimide (1e)




¹³C NMR. *N*-(5-selenomethyl)pentylphthalimide (1e)




^{77}Se NMR. *N*-(5-selenomethyl)pentyl)phthalimide (1e)




¹H NMR 10b-hydroxy-1,3,4,10b-tetrahydro-6H-[1,4]selenazino[3,4-a]isoindol-6-one (2a)




¹³C NMR 10b-hydroxy-1,3,4,10b-tetrahydro-6H-[1,4]selenazino[3,4-a]isoindol-6-one (2a)




^{77}Se NMR 10b-hydroxy-1,3,4,10b-tetrahydro-6H-[1,4]selenazino[3,4-a]isoindol-6-one (2a)




¹H NMR. 11b-hydroxy-1,4,5,11b-tetrahydro-3H,7H-[1,4]selenazepino[3,4-a]isoindol-7-one (2b)




¹³C NMR. 11b-hydroxy-1,4,5,11b-tetrahydro-3H,7H-[1,4]selenazepino[3,4-a]isoindol-7-one (2b)




⁷⁷Se NMR. 11b-hydroxy-1,4,5,11b-tetrahydro-3H,7H-[1,4]selenazepino[3,4-a]isoindol-7-one (2b)




¹H NMR. 9b-hydroxy-1-(selenomethyl)-1,2,3,9b-tetrahydro-5H-pyrrolo[2,1-a]isoindol-5-one (3b)




^{13}C NMR. 9b-hydroxy-1-(selenomethyl)-1,2,3,9b-tetrahydro-5H-pyrrolo[2,1-a]isoindol-5-one (3b)




^{77}Se NMR. 9b-hydroxy-1-(selenomethyl)-1,2,3,9b-tetrahydro-5H-pyrrolo[2,1-a]isoindol-5-one (3b)




COSY 9b-hydroxy-1-(selenomethyl)-1,2,3,9b-tetrahydro-5H-pyrrolo[2,1-a]isoindol-5-one (3b)







HSQC-DEPT 9b-hydroxy-1-(selenomethyl)-1,2,3,9b-tetrahydro-5H-pyrrolo[2,1-a]isoindol-5-one (3b)






HMQC 9b-hydroxy-1-(selenomethyl)-1,2,3,9b-tetrahydro-5H-pyrrolo[2,1-a]isoindol-5-one (3b)




1D NOE. 9b-hydroxy-1-(selenomethyl)-1,2,3,9b-tetrahydro-5H-pyrrolo[2,1-a]isoindol-5-one (3b)












¹H NMR. 9b-hydroxy-1,2,3,9b-tetrahydro-5H-pyrrolo[2,1-a]isoindol-5-one (4b)




¹³C NMR. 9b-hydroxy-1,2,3,9b-tetrahydro-5H-pyrrolo[2,1-a]isoindol-5-one (4b)




¹H NMR. 5H-pyrrolo[2,1-a]isoindol-5-one (5b)




¹³C NMR. 5H-pyrrolo[2,1-a]isoindol-5-one (5b)




¹H NMR. 10b-hydroxy-1-(selenomethyl)-1,3,4,10b-tetrahydropyrido[2,1-a]isoindol-




¹³C NMR. 10b-hydroxy-1-(selenomethyl)-1,3,4,10b-tetrahydropyrido[2,1-a]isoindol-6(2H)-one (3d)





^{77}Se NMR. 10b-hydroxy-1-(selenomethyl)-1,3,4,10b-tetrahydropyrido[2,1-a]isoindol-6(2H)-one (3d)




COSY. 10b-hydroxy-1-(selenomethyl)-1,3,4,10b-tetrahydropyrido[2,1-a]isoindol-6(2H)-one (3d)







HSQC. 10b-hydroxy-1-(selenomethyl)-1,3,4,10b-tetrahydropyrido[2,1-a]isoindol-6(2H)-one (3d)






HMBC. 10b-hydroxy-1-(selenomethyl)-1,3,4,10b-tetrahydropyrido[2,1-a]isoindol-6(2H)-one (3d)






1D NOE. 10b-hydroxy-1-(selenomethyl)-1,3,4,10b-tetrahydropyrido[2,1-a]isoindol-6(2H)-one (3d)














¹H NMR. 13b-hydroxy-1,4,5,6,7,13b-hexahydro-3H,9H-[1,4]selenazonino[3,4-a]isoindol-9-one (2e)



¹³C NMR. 13b-hydroxy-1,4,5,6,7,13b-hexahydro-3H,9H-[1,4]selenazonino[3,4-a]isoindol-9-one (2e)



^{77}Se NMR. 13b-hydroxy-1,4,5,6,7,13b-hexahydro-3H,9H-[1,4]selenazonino[3,4-a]isoindol-9-one (2e)



References

¹ (a) O. Shvydkiv, K. Nolan and M. Oelgemoller, *Beilstein J. Org. Chem.* 2011, **7**, 1055-1063; (b) O. Shvydkiv, S. Gallagher, K. Nolan and M. Oelgemoller, *Org. Lett.* 2010, **12**, 5170-5173.

² R. Grigg, V. Sridharan, P. Stevenson, S. Sukirthalingam and T. Worakun, *Tetrahedron* 1990, **46**, 4003-4018.